Supercharged immune cells take on Hard-to-Treat blood cancers

This study tests a new approach for people with relapsed or chemotherapy-resistant B-cell cancers like chronic lymphocytic leukemia and indolent B-cell lymphoma. Researchers take a patient's own T cells (a type of immune cell), modify them in the lab to target a protein called CD19 on cancer cells, and then return them to the patient along with a chemotherapy drug called cyclophosphamide. The goal is to see if this treatment is safe and effective at controlling the disease.